# Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma

> **NCT04021420** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 21 (estimated)

## Conditions studied

- Melanoma
- Metastatic Melanoma

## Interventions

- **DEVICE:** SONOCLOUD
- **DRUG:** Nivolumab Injection

## Key facts

- **NCT ID:** NCT04021420
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-24
- **Primary completion:** 2022-01-01
- **Final completion:** 2023-07-05
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2020-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04021420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04021420, "Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04021420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*